EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment

Kyungchan Min iD, Chuang-Ming Zheng iD, Sujeong Kim, Hyun Kim iD, Minji Lee, Xuan-Mei Piao iD, Young Joon Byun, Yunjae Kim, Yanghyun Joo, Beomki Cho, Seongmin Moon, Won Tae Kim und 3 weitere

International Journal of Molecular Sciences · 17.10.2024 · 25 (20) · 11157

DOI: 10.3390/ijms252011157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.10.2024. Verfasst von Kyungchan Min und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Microbiota, BCG Vaccine, RNA, Ribosomal, 16S. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Korea Health Industry Development Institute, Basic Science Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have identified a urinary microbiome, dispelling the myth of urine sterility. Intravesical bacillus Calmette–Guérin (BCG) therapy is the preferred treatment for intermediate to high-risk non-muscle-invasive bladder cancer (BCa), although resistance occurs in 30–50% of cases. Progression to muscle-invasive cancer necessitates radical cystectomy. Our research uses 16S rRNA gene sequencing to investigate how the urinary microbiome influences BCa and its response to BCG therapy. Urine samples were collected via urethral catheterization from patients with benign conditions and non-muscle-invasive BCa, all of whom underwent BCG therapy. We utilized 16S rRNA gene sequencing to analyze the bacterial profiles and metabolic pathways in these samples. These pathways were validated using a real metabolite dataset, and we developed predictive models for malignancy and BCG response. In this study, 87 patients participated, including 29 with benign diseases and 58 with BCa. We noted distinct bacterial compositions between benign and malignant samples, indicating the potential role of the toluene degradation pathway in mitigating BCa development. Responders to BCG had differing microbial compositions and higher quinolone synthesis than non-responders, with two Bifidobacterium species being prevalent among responders, associated with prolonged recurrence-free survival. Additionally, we developed highly accurate predictive models for malignancy and BCG response. Our study delved into the mechanisms behind malignancy and BCG responses by focusing on the urinary microbiome and metabolic pathways. We pinpointed specific beneficial microbes and developed clinical models to predict malignancy and BCG therapy outcomes. These models can track recurrence and facilitate early predictions of treatment responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsMicrobiotaBCG VaccineRNA, Ribosomal, 16SHumansMaleFemaleAgedMiddle AgedBacteria

Stichwörter der Autor:innen

16S rRNA gene sequencingBifidobacteriumBladder cancerIntravesical BCG treatmentQuinoloneUrinary microbiome

Substanzen

BCG VaccineRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
  • Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea.
  • Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
  • Department of Convergence of Medical Science, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea.
  • Genome and Company, Seongnam 13486, Republic of Korea.

ORCID-Profile: Kyungchan Min, Chuang-Ming Zheng, Hyun Kim, Xuan-Mei Piao, Seok Joong Yun

Förderung

  • Ministry of Education
  • Korea Health Industry Development Institute
  • Basic Science Research Program
  • Regional Innovation Strategy (RIS)
  • BK21 FOUR program
  • Bio and Medical Technology Development Program

Zitieren

APA

Min, K., Zheng, C. M., Kim, S., Kim, H., Lee, M., Piao, X. M., Byun, Y. J., Kim, Y., Joo, Y., Cho, B., Moon, S., Kim, W. T., Kang, H. W., Park, H., & Yun, S. J. (2024). Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment. International Journal of Molecular Sciences, 25(20), 11157. https://doi.org/10.3390/ijms252011157

Vancouver

Min K, Zheng CM, Kim S, Kim H, Lee M, Piao XM, et al. Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment. International Journal of Molecular Sciences. 2024;25(20):11157. doi:10.3390/ijms252011157

BibTeX
@article{Min2024,
  author = {Min, Kyungchan and Zheng, Chuang-Ming and Kim, Sujeong and Kim, Hyun and Lee, Minji and Piao, Xuan-Mei and Byun, Young Joon and Kim, Yunjae and Joo, Yanghyun and Cho, Beomki and Moon, Seongmin and Kim, Won Tae and Kang, Ho Won and Park, Hansoo and Yun, Seok Joong},
  title = {Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {20},
  pages = {11157},
  doi = {10.3390/ijms252011157}
}
Kostenlos starten →